Collection

Advances in Lymphoma Discovery and Treatment

Submission status
Open
Open for submission from
01 April 2023
Submission deadline
30 June 2024

Lymphomas are a group of haematological malignancies that are amongst the top ten cancers worldwide. Broadly, they may be divided into Hodgkin lymphomas and non-Hodgkin lymphomas of B-cell or T/NK-cell immunophenotypic subtypes. In terms of therapeutics, patients commonly receive multi-agent chemoimmunotherapy in the frontline setting. In the relapsed setting, haematopoetic stem cell transplant and CAR-T therapy remain the only potentially-curative options for eligible patients, with other agents such as targeted small molecule inhibitors, immune checkpoint inhibitors, and novel drugs providing additional options for disease control. Recently, advances in “omic” technologies have provided the opportunity to stratify lymphomas into distinct molecular subtypes, contributing to an improved understanding of disease pathobiology. However, the clinical implications of these findings often remain unclear at this juncture.

This Topical Collection aims to collect papers dealing with the latest discoveries in lymphoma, particularly those that impact on clinical management and therapeutics. We welcome both original articles on clinical and translational research on lymphomas, as well as review articles that integrate knowledge in the field.

Keywords: Lymphoma; Hematology; Therapeutics; Blood; Genomics

Editors

  • Jason Yongsheng Chan Jason Yongsheng Chan  &

    Jason Yongsheng Chan

    Assistant Professor Jason Chan, National Cancer Centre Singapore, Singapore He completed specialist training at the National Cancer Centre Singapore and subsequently obtained a Doctorate from the Cancer Science Institute of Singapore. He is Consultant Medical Oncologist at the National Cancer Centre Singapore and Assistant Professor at Duke-NUS Medical School. He currently serves as Director of the Cancer Discovery Hub and Deputy Director of Medical Oncology Research at the National Cancer Centre, Singapore.

  • Choon Kiat Ong Choon Kiat Ong

    Choon Kiat Ong

    Associate Professor Ong Choon Kiat, National Cancer Centre Singapore, Singapore He is the Principal Investigator of Lymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore. He holds an appointment as a Senior Research Scientist at the Genome Institute of Singapore and an Associate Professor at the Duke-NUS Medical School. He obtained his BSc (Hon) in 2000 and PhD in 2006 from the National University of Singapore. During his post-doctoral training, he has led the genomic research in various cancers prevalent in Asia including lymphoma, cholangiocarcinoma and fibroepithelial tumors of the breast.

Articles (2 in this collection)